DK1814595T3 - Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne - Google Patents

Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne

Info

Publication number
DK1814595T3
DK1814595T3 DK05810600.6T DK05810600T DK1814595T3 DK 1814595 T3 DK1814595 T3 DK 1814595T3 DK 05810600 T DK05810600 T DK 05810600T DK 1814595 T3 DK1814595 T3 DK 1814595T3
Authority
DK
Denmark
Prior art keywords
disrupts
oligonucleotide
cancer
agent
treatment
Prior art date
Application number
DK05810600.6T
Other languages
Danish (da)
English (en)
Inventor
Martin Gleave
Gabriella Zupi
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of DK1814595T3 publication Critical patent/DK1814595T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK05810600.6T 2004-11-23 2005-11-22 Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne DK1814595T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52294804P 2004-11-23 2004-11-23
US52296004P 2004-11-24 2004-11-24
PCT/CA2005/001775 WO2006056054A1 (en) 2004-11-23 2005-11-22 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels

Publications (1)

Publication Number Publication Date
DK1814595T3 true DK1814595T3 (da) 2014-03-31

Family

ID=36497699

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05810600.6T DK1814595T3 (da) 2004-11-23 2005-11-22 Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne

Country Status (11)

Country Link
US (2) US20080014198A1 (https=)
EP (1) EP1814595B1 (https=)
JP (1) JP4980919B2 (https=)
AU (1) AU2005309274B2 (https=)
CA (1) CA2584646C (https=)
DK (1) DK1814595T3 (https=)
ES (1) ES2456017T3 (https=)
PL (1) PL1814595T3 (https=)
PT (1) PT1814595E (https=)
SI (1) SI1814595T1 (https=)
WO (1) WO2006056054A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100768109B1 (ko) 1999-02-26 2007-10-17 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
DK1814595T3 (da) * 2004-11-23 2014-03-31 Univ British Columbia Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne
AU2006291990B2 (en) * 2005-09-13 2012-05-31 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
CN102666585B (zh) 2009-11-24 2015-02-18 阿莱斯亚生物疗法股份有限公司 抗簇蛋白抗体和抗原结合片段及其减小肿瘤体积的用途
WO2012123823A1 (en) 2011-03-15 2012-09-20 The University Of British Columbia Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
WO2013123588A1 (en) * 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
MD20140101A2 (ro) * 2013-02-22 2015-02-28 Alethia Biotherapeutics Inc. Utilizarea concomitentă a unui inhibitor al clusterinei cu un inhibitor al EGFR pentru tratamentul cancerului

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6365345B1 (en) * 1993-12-23 2002-04-02 Biognostik Gesellscahft Für Biomokekulare Diagnostik mbH Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a role
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
ATE267207T1 (de) * 1996-02-14 2004-06-15 Isis Pharmaceuticals Inc Kohlenhydratmodifizierte luckenhafte oligonukleotide
US5910583A (en) * 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
KR100768109B1 (ko) * 1999-02-26 2007-10-17 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
AU2003237616B2 (en) * 2002-01-17 2007-07-05 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US7019017B2 (en) * 2002-05-14 2006-03-28 Baylor College Of Medicine Small molecule inhibitors of HER2 expression
NZ538288A (en) * 2002-08-21 2008-04-30 Univ British Columbia Treatment of melanoma by reduction in clusterin levels
JP4717633B2 (ja) * 2002-08-21 2011-07-06 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 癌関連タンパク質を標的とするＲＮＡｉプローブ
US20040224914A1 (en) * 2003-04-18 2004-11-11 The University Of British Columbia Method for treatment of angiogenic disorders
WO2004092378A2 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
DK1814595T3 (da) * 2004-11-23 2014-03-31 Univ British Columbia Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne

Also Published As

Publication number Publication date
CA2584646A1 (en) 2006-06-01
JP2008520591A (ja) 2008-06-19
CA2584646C (en) 2015-11-03
AU2005309274B2 (en) 2011-07-21
US20110142827A1 (en) 2011-06-16
AU2005309274A1 (en) 2006-06-01
US20080014198A1 (en) 2008-01-17
PL1814595T3 (pl) 2014-08-29
WO2006056054A1 (en) 2006-06-01
EP1814595A4 (en) 2009-04-15
EP1814595A1 (en) 2007-08-08
JP4980919B2 (ja) 2012-07-18
PT1814595E (pt) 2014-04-02
ES2456017T3 (es) 2014-04-21
SI1814595T1 (sl) 2014-06-30
EP1814595B1 (en) 2014-01-08

Similar Documents

Publication Publication Date Title
PL2217031T3 (pl) Efektywna sygnalizacja za pośrednictwem kanału dostępu
IL185679A0 (en) Anti-proliferative combination therapy using certain platinum-based chemotherapeutic agents and taxanes
CA111398S (en) Bottle
BRPI0718146A2 (pt) Dispositivos de infusão e métodos
IL191092A0 (en) Shared signaling channel
CA111399S (en) Bottle
PT1849470T (pt) Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase
AU313179S (en) Sprocket
CY1108399T1 (el) Τετραϋδροπυριδοθειοφαινια
CA111400S (en) Bottle
DE602005021959D1 (de) Substituierte diazaspiroä4.5üdecanderivate und der
WO2006113767A3 (en) Hgf beta chain variants
AU313180S (en) Sprocket
DK1814595T3 (da) Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne
WO2008006883A3 (en) Benzopyranopyrazoles
WO2006125813A3 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
WO2006125815A3 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
ES1056496Y (es) Tapon para los oidos.
NO20052744D0 (no) Tannpleieutstyr.
EP1754473A4 (en) ANTITUMORAL MEDIUM
ES1058499Y (es) Perfil de alero ventilado.
CA117639S (en) Trellis
ES1056769Y (es) Dispositivo para señalizaciones.
ES1055191Y (es) Conjunto de toma de corriente con seguridad.
ITPR20050019A1 (it) Forno crematorio e procedimento per cremare.